Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20:596-604.Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM (2013) Treatment of estrogen receptor-positive breast cancer. Curr Med Chem 20:596–604. : 10.2174/092986713804999303F. Lumachi, A. ...
Thus, research efforts have focused on finding alternative therapies to trastuzumab and lapatinib for the treatment of Her2-positive breast cancer. Efforts aimed at understanding the mechanism of action of trastuzumab and lapatinib and the causes of resistance have led to the identification of several ...
COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER Methods for treating estrogen receptor positive (ER+) breast cancer, comprising administering to a subject in need thereof, a BET bromodomain inhibitor in ... E Campeau,O Kharenko,DHETH Van 被引量: 0发表: 2022年...
Many early breastcancersdo not produce symptoms and are found on screening procedures. For those cancers that do produce symptoms, the most common sign of breast cancer is a new lump or mass in the breast. In addition, the following are possible signs of breast cancer: Thickening or lump in...
Researchers from the Early Breast Cancer Trialists' Collaborative Group analyzed data from 88 clinical trials involving 62,923 women with ER-positive breast cancer. The patients all received endocrinetherapyfor five years and were free of cancer when they stopped therapy. ...
Can we use inhibitors of mutp53 for future treatment Her2-positive breast cancer? Is it important to detect the status of p53 in Her2-positive breast cancer? Breast cancer classification Breast cancer, despite its heterogeneity, can be categorized into five subtypes: luminal type A (estrogen recep...
HER2-positive (+) breast cancer is an aggressive disease with poor prognosis, a narrative that changed drastically with the advent and approval of trastuzumab, the first humanized monoclonal antibody targeting HER2. In addition to another monoclonal anti
Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.
The new data suggested that women with ER-positive breast cancer should at least consider taking anti-estrogen therapy beyond five years, the researchers said. Doctors have long known that five years of tamoxifen reduces recurrence by approximately half during treatment, and by nearly a third over...
What is HER2-positive breast cancer? For about 20% of women with breast cancer, the cancer cells test positive for HER2. HER2 is a growth-promoting protein located on the surface of some cancer cells. HER2-positive breast cancers tend to grow more rapidly and spread more aggressively. ...